Partnering to treat an Orphan Disease Duchenne Muscular Dystrophy

合作治疗孤儿病杜氏肌营养不良症

• 批准号: 8599246
• 负责人: STANLEY C FROEHNER
• 金额: $ 293.31万
• 依托单位: HUGO W. MOSER RES INST KENNEDY KRIEGER
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-06-18 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8599246
• 关键词: Adolescent; Adrenal Cortex Hormones; Adverse effects; Affect; Award; Clinic; Clinical Trials; Country; Development; Disease; Dose; Double-Blind Method; Drug Kinetics; Duchenne muscular dystrophy; Institutes; Investments; Life; Muscular Dystrophies; Myocardium; Nature; Oral; Pediatric Hospitals; Pharmaceutical Preparations; Pharmacodynamics; Pharmacological Treatment; Phase; Phenotype; Placebo Control; Randomized; Rare Diseases; Research Personnel; Safety; Site; Skeletal Muscle; Toxicology; Universities; Washington; boys; efficacy testing; experience; functional improvement; mouse model; novel therapeutics; preclinical study; safety study

Duchenne muscular dystrophy (DMD) is a severely disabling and fatal disorder. It is the most common muscular dystrophy, affecting 1:5000 boys worldwide; however, it is an orphan disease which has received relatively little investment toward the development of novel therapeutics. Consequently, there are no good treatments for this devastating disorder. In this application, Dr. Kathryn Wagner from the Kennedy Krieger Institute and Dr. Stanley Froehner from the University of Washington propose to repurpose a Sanofi compound for Duchenne muscular dystrophy. In the UH2 portion of the award, Dr. Froehner will test efficacy of the compound in the mdx/utr mouse model of DMD and will oversee juvenile toxicology studies performed by a CRO. Following timely IND filing with the FDA, Dr. Wagner and Dr. Jerry Mendell at Nationwide Children's Hospital will conduct Phase Ib SAD and MAD studies for safety and dose finding in a limited number of DMD subjects. In the UH3 portion of the award, Phase IIa studies in DMD boys will be conducted at multiple sites across the country. Investigators at all sites have active DMD clinics and experience in DMD clinical trials. The Phase IIa study will determine if the compound results in functional improvement in DMD as well as whether sustained administration is safe and well tolerated in DMD. Given the life threatening and disabling nature of DMD, the Phase IIa is anticipated to be the pivotal clinical trial for seeking provisional FDA approval.

杜氏肌营养不良症（DMD）是一种严重致残和致命的疾病。它是最常见的肌营养不良症，影响全世界1：5000的男孩;然而，它是一种孤儿疾病，在开发新疗法方面获得的投资相对较少。因此，没有很好的治疗这种毁灭性的疾病。在本申请中，Kennedy Krieger研究所的Kathryn瓦格纳博士和华盛顿大学的Stanley Froehner博士建议将赛诺菲化合物重新用于杜氏肌营养不良症。在该奖项的UH 2部分，Froehner博士将测试该化合物在DMD的mdx/utr小鼠模型中的疗效，并将监督由CRO进行的青少年毒理学研究。在及时向FDA提交IND申请后，Nationwide Children's Hospital的瓦格纳博士和杰里·门德尔博士将在有限数量的DMD受试者中进行Ib期SAD和MAD研究，以确定安全性和剂量。在该奖项的UH 3部分，DMD男孩的IIa期研究将在全国多个地点进行。所有研究中心的研究者都有活跃的DMD诊所和DMD临床试验经验。IIa期研究将确定该化合物是否导致DMD的功能改善，以及持续给药在DMD中是否安全且耐受良好。鉴于DMD的生命威胁和致残性，预计IIa期临床试验将成为寻求FDA临时批准的关键临床试验。